Jörg Chromik Selected Research

Therapeutics

12/2023	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
8/2022	Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jörg Chromik Research Topics

Disease

2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 08/2022
2	Neoplasms (Cancer) 03/2022 - 01/2006
1	Leukemia 03/2022
1	Lymphoma (Lymphomas) 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2017

Drug/Important Bio-Agent (IBA)

1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 12/2023
1	enasidenibIBA 12/2023
1	siremadlinIBA 03/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021
1	crenigacestatIBA 01/2021
1	Notch ReceptorsIBA 01/2021
1	luspaterceptIBA 10/2017
1	VaccinesIBA 01/2006
1	AntigensIBA 01/2006
1	Peptides (Polypeptides)IBA 01/2006
1	EpitopesIBA 01/2006

Therapy/Procedure

2	Therapeutics 12/2023 - 08/2022
1	Aftercare (After-Treatment) 08/2022
1	Drug Therapy (Chemotherapy) 08/2022
1	Consolidation Chemotherapy 08/2022
1	Erythrocyte Transfusion 10/2017